WHITEFISH, MT / ACCESSWIRE / December 3, 2014 / Cannabis based medicine is being widely adopted as the next exciting special interest sector of the biotech community. With GW Pharmaceuticals plc (GWPH) and others conducting clinical trials targeting important indications like cancer pain and arthritis, the data collected so far has suggested that cannabinoids could have far-reaching beneficial effects on the human body.
InMed Pharmaceuticals Inc. (IMLFF), a clinical-stage drug discovery and development company focused on the therapeutic potential of cannabinoids, recently announced that it retained Tiberend Strategic Advisors to manage its investor and public relations programs. The New York-based corporate communications firm specializes in emerging healthcare companies.
In a recent article appearing in The Scientist, InMed Pharmaceuticals' President and CEO Craig Schneider outlined why the company was focusing on the biotech side of the business: "We looked at GW and saw that the shift toward pharmacological development of marijuana is already happening … we see the likes of Otsuka, Novartis, and Eli Lilly diving into the space and we want to be part of that."
Focus on Biotech
Tiberend Strategic Advisors is a full service corporate communications firm that has made a name for itself in the healthcare and life sciences industry. Founded in 1989, the firm's mission is to provide expert public and investor relations counsel to companies along the entire development lifecycle - from emerging, clinical-stage to publicly-traded and revenue generating companies in the space.
Within the biotech industry, Tiberend sponsors a number of conferences including Sachs Associates' Cancer Bio Partnering & Investment Forum, Biotech Showcase, and the Bio CEO & Investor Conference. Gregory Tiberend heads the team at Tiberend Strategic Advisors with many years of experience in both the public relations and healthcare industry. Over his career, Mr. Tiberend has counseled more than 50 companies in the areas of biotechnology, specialty pharmaceutical, generic pharmaceutical, medical service, diagnostics, healthcare services, and financial services, among others.
Taking a Unique Approach
InMed Pharmaceuticals' hiring of Tiberend Strategic Advisors highlights its focus on the biotech side of the cannabis industry. By leveraging its proprietary Intelligent Cannabinoid Drug Design Platform, the company aims to rapidly identify promising new bioactive compounds in cannabis and create an accelerated pathway for drug development and commercialization of between three and five years.
So far, the company has identified two compounds to treat glaucoma and arthritis, known as CTI-085 and CTI-091, respectively. CTI-085 is a topical formulation containing a proprietary cannabinoid compound along with non-cannabis ingredients, while CTI-091 is a mixture of cannabinoids and non-cannabis ingredients to relieve joint pain and swelling from arthritis.
Through a partnership with researchers at the University of British Columbia, the company is also developing a drug delivery system that effectively transports these therapies to the intended tissue without significant dilution. Cannabinoids have traditionally been difficult to deliver due to their lipophilic nature - which leads to them combining with lipids or fats in the body before reaching a target.
InMed Pharmaceuticals is rapidly moving forward with its clinical programs with the help of its proprietary platform. President & CEO Craig Schneider heads the company with over 20 years of capital markets experience, while CSO Dr. Sazzad Hossain, Ph.D., M.Sc., has over 20 years of experience with new drug development and a history with the Biotechnology Research Institute in Canada.
In addition to its clinical programs, the company has started developing individual strains and clones that will produce raw material for future research. The team will study plant development and secondary metabolite biosynthesis in both indoor and outdoor conditions that meet high quality standards. These efforts are similar to GW Pharma's Cannabinoid Research Institute programs.
With a market capitalization of just over $6 million, investors in both the cannabis and biotech industries may want to take a closer look at the stock. Management's industry expertise and the company's proprietary platform could set the stage for drug discovery and development that takes less than five years instead of more than 10 years - yielding a nearer term opportunity in a rapidly growing niche market.
Click here to learn more about InMed Pharma, which recently changed its name from Cannabis Technologies: http://www.cannabisfn.com/mdc/cannabis-technologies-inc/.
Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two. For full disclosure please visit: http://www.cannabisfn.com/legal-disclaimer/.
SOURCE: Emerging Growth LLC